First Subject Enrolled in Phase Ⅱ Clinical Trial of Luye Pharma’s TAAR1/5-HT2CR-targeted Investigational Drug for Treating ...
Shanghai, April 8th, 2026 – Luye Pharma Group today announced that the first subject has been enrolled in a Phase Ⅱ clinical trial in China evaluating its LY03020 for the treatment of schizophrenia. Filed through China’s Class 1 pathway for innovative drugs, LY03020 is the ...
April 08,2026
Luye Pharma Announces 2025 Financial Results
- New product sales up 56.8% -
- Net profit attributable to parent company up 31.1% -
Shanghai, March 31, 2026 -- Luye Pharma Group (2186.HK) today announced its annual results for fiscal year 2025 and the latest developments.
In the reporting period, the group’s revenue was ...
April 01,2026
13
2026-03
Luye Pharma Forms Strategic Partnership with Sinopharm Group and Sinopharm CNCM to Commercialize Mimeixin® and Other Products
08
2026-01
NMPA Accepts the NDA for Luye Pharma’s Ruoxinlin® for the New Indication of Generalized Anxiety Disorder
24
2025-12
Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Injectable Antipsychotics in the Chinese Mainland
07
2025-12
Luye Pharma’s Five New Products Included in China’s 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug List
24
2025-11
Luye Pharma Receives FDA Clearance of IND Application for Its Next-generation 5-HT2AR Inverse Agonist/5-HT2CR Antagonist LY03017
28
2025-08
Luye Pharma Announces 2025 Half-Year Results
18
2025-08
All Patients Enrolled for the Phase III Clinical Trial of Luye Pharma’s Ruoxinlin® for Treating Generalized Anxiety Disorder
03
2025-08
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR
10
2025-04
Luye Pharma Launches Its Transdermal Patch Rotigotine Luye in the UK for the Treatment of Parkinson’s Disease and Restless Legs Syndrome
07
2025-04
Luye Pharma’s Class 1 Innovative Antidepressant Ruoxinlin® Approved for Marketing in Macao
